Tweet
Patience . . . .
Wait until the record date is past, or else you have to pay the divy!
Originally posted by dmk112
OFG may go to 15 and that is when I will short it 
-
Originally posted by New-born baby
Good reminder, I forgot about that little perk with dividends when shorting.. ouch!Comment
-
After I take my dividend and collect my profits I may go short myself, if the price action looks weak. For now, my long position is looking good.Originally posted by dmk112Comment
-
Hahaha! Watch OFG run!Comment
-
The time has come!Originally posted by spikefader At last......a Vulcan's revenge on OFG!Comment
-
Calling Dr. Jiesen; Calling Dr. Jiesen.
Dr. Jiesen, Calling Dr. Jiesen.
You are wanted on the FA floor. You are wanted on the FA floor.
Take a look at this one. The chart says, "Buy me; you won't be sorry."
What's the FA on this one? Another AMLN?
Comment
-
-
hmmm, looks like you found a pretty good one there, NBB...
FDA approval is always key to a biotech's success. And Biovail has just received approval for their pain medication. Hooray for them! The stock definitely deserves to get a premium now for this, but how much? The 25% they've got already yesterday may be all that drug is worth, considering they're already at a $3.6B market cap. But I guess it depends on the market size potential for the drug. It also depends on what else this company has going for it. The success with Tramadol is an indication that other successes will follow, and so makes a good case for a long-term investment here. If I were to buy this, though, I wouldn't go in right now (at least not all the way). I'd save some cash for a pull-back. If it comes back to $19 or $18, back to where it was before approval, then it's a screaming buy. Right now, you may want to wait until the novelty of the approval hype wears off a bit.
Fundamentally, though, the company seems to be doing ok. They're making a profit (usually) and they don't have to sell shares to keep the company afloat. The balance sheet shows about a $0 book value, which is unimpressive, but they also do have about $1B in intangible value, and that is important, if not intrinsically valuable. Because it's a pretty established company, you're paying quite a bit for it at $3.6B, and therefore the upside potential is rather limited. So I guess you'd want to play this for $3-5 swings at a time, if you wanted to maximize profits. You probably won't see this trading at $50 anytime soon. But if you sock away a few shares for a long time, who knows? It could play out very nicely. I haven't looked too deeply into this company, so I couldn't say whether it'll be another AMLN, but I seriously doubt it. Though the market for their products is no doubt huge, they're not exactly a one-of-a-kind or first to market in their category. So margins will be tighter and competition will be tough.
Overall though, it looks like a thumbs up so far on this one, but remember that it's still a biotech, and can pull an ABRX or AAII on you just as easily as any of them, so watch out, and if you haven't really done enough homework on it, stay out, or at least use a stop for safety.
Oh, and they're Canadian, eh.Comment
-
Ofg...
Originally posted by dmk112
You mean OFG, right? Filling the gap down to 14? Looks like a nice place to pick up some shares, before it continues on with its run to 15. I think that OFG seeing 15 this month is a near certainty, unless of course it gaps up to 16.Comment
-
Originally posted by jiesen
No i actually mean BVF, I think I was looking at both and blended the symbols LOLComment
-
OFG today
Men,
Here's OFG today. When is earnings coming out? And what is the ex-date for the divy? Can someone tell me?
This thing is primed for a surprize announcement. If it is good, it could pop $2.
On the other hand, if it is bad, it could fall down $2.
It doesn't like to get too close to that 50 day.Comment
-
I'm still in stalking mode to rebuy OFG. I wouldn't mind a little more profit from it.Comment
-
AMLN scrip numbers are looking even better!
AMLN scrip numbers:
Week ending 9/2: Byetta 8813 of which 7455 were new. Symlin: 1508 of which 993 were new.
That's an increase of 25% for Byetta scrips over last week.
This also means that revenue is up 20% this week.
Comment
-
Sold NGPS today
Got out of NGPS at 27.8, about a 14% gain from where I bought it (24.4). Not quite as much as I wanted out of this one, but not bad either.Comment
Comment